Lv3
390 积分 2023-03-13 加入
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
24天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
24天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
24天前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
24天前
已完结
Pembrolizumab in HER2-Positive Gastric Cancer
24天前
已完结
Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity
1个月前
已完结
Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer
1个月前
已完结
Targeting fibroblast-like synoviocytes with CDK4/6 inhibitors as a novel, non-immunosuppressive treatment strategy for rheumatoid arthritis
2个月前
已完结
Human germline gain-of-function in STAT6: from severe allergic disease to lymphoma and beyond
3个月前
已完结
Discovery of E3 Ligase Ligands for Target Protein Degradation
4个月前
已完结
皖公网安备34019202002308
